Houston, TX – October Xth, 2025 – OmniScience has been named a finalist in the Duke Clinical Research Institute (DCRI) Think Tank: Innovative Ideas to Improve Clinical Trial Efficiencies, joining a select group of companies working to advance the future of clinical research.

The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world renowned for its rigorous methodology, real-world research, and commitment to transforming health care through innovation. The program brings together cutting-edge technology partners to improve trial design, accelerate insights, and reduce the time it takes to bring new therapies to patients.

OmniScience was selected for its work on Vivo, an agentic AI platform designed to unify clinical data and provide real-time, explainable insights to trial teams. By proactively identifying issues such as missing endpoints, operational risk, and safety signals, Vivo empowers clinical teams to act faster and more confidently across complex portfolios.

“We’re thrilled to be recognized by the Duke Clinical Research Institute” says Angela Holmes, OmniScience CEO. “Being named a finalist in this ThinkTank initiative affirms the growing momentum behind AI-powered solutions to advance clinical trial efficiencies. We’re looking forward to demonstrating how Vivo’s agentic AI can streamline trials, support smarter decisions, and ultimately improve outcomes for patients.”

This milestone builds on a year of momentum for OmniScience, with growing adoption of Vivo across biopharma and real-world validation of its ability to unify data, get instant answers, and act faster.